Summary
Global Markets Direct’s, ‘Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Pipeline Review, H2 2016’, provides in depth analysis on Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) targeted pipeline therapeutics.
The report provides comprehensive information on the Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B)
- The report reviews Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
Anthera Pharmaceuticals‚ Inc.
Eli Lilly and Company
GlaxoSmithKline Plc
Merck KGaA
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) Overview 7
Therapeutics Development 8
Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Products under Development by Stage of Development 8
Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Products under Development by Therapy Area 9
Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Products under Development by Indication 10
Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Products under Development by Companies 14
Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Companies Involved in Therapeutics Development 23
Anthera Pharmaceuticals‚ Inc. 23
Eli Lilly and Company 24
GlaxoSmithKline Plc 25
Merck KGaA 26
Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Drug Profiles 27
atacicept - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
belimumab - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
blisibimod - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
BLyS-gel - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Monoclonal Antibodies to Inhibit BAFF for B-Cell Lymphoma - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Monoclonal Antibody to Inhibit BAFF and IL-17 for Immunology - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
OSX-100 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
OSX-110 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
RCT-18 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Dormant Projects 48
Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Discontinued Products 49
Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Featured News & Press Releases 50
Jun 28, 2016: Anthera Provides Clinical Program Update for Blisibimod 50
Jun 08, 2016: New Phase III data shows greater treatment response with GSK’s Benlysta (belimumab) vs placebo in patients with highly active SLE 51
Mar 03, 2016: New long-term organ damage analysis published for GSK’s Benlysta (belimumab) 53
Nov 07, 2015: GSK announces positive results from phase III BLISS-SC study of Benlysta (belimumab) administered subcutaneously in patients with systemic lupus erythematosus 54
Jun 16, 2015: Anthera Pharmaceuticals Has Reached Enrollment Target in CHABLIS-SC1 Phase 3 Clinical Trial With Blisibimod 55
Jun 04, 2015: Anthera Pharmaceuticals Announces Additional Data on Patient-Reported Outcomes From Phase 2b PEARL-SC Blisibimod Study 56
Mar 16, 2015: Anthera Pharmaceuticals Announces Completion of Interim Analysis from Phase 3 Trial with Blisibimod for IgA Nephropathy 56
Feb 10, 2015: Anthera Pharmaceuticals Announces Completion of Interim Analysis from Phase 3 Trial with Blisibimod for Systemic Lupus Erythematosus 56
Dec 30, 2014: Anthera Pharmaceuticals Announces Lupus Symposium During 2015 JP Morgan Healthcare Conference 57
Oct 01, 2014: Anthera Pharmaceuticals Announces Update On Strategic Partnership Discussions For Blisibimod 58
Sep 25, 2013: Anthera Pharmaceuticals Announces Emerging Data from Phase 2 Open-Label Extension Study to be Presented at the ACR/ARHP 2013 Annual Scientific Meeting 58
Jul 23, 2013: NICE consults on belimumab for systemic lupus erythematosus 59
Jun 24, 2013: Anthera Pharma Initiates BRIGHT-SC Phase II Clinical Study In IgA Nephropathy With Blisibimod 60
May 07, 2013: Anthera Pharma Announces Additional Data From Phase IIb PEARL-SC Blisibimod Study 60
Apr 03, 2013: GlaxoSmithKline Starts Phase III Study Of Benlysta In Patients With Vasculitis 61
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64
List of Tables
Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 (Contd..1) 16
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 18
Number of Products by Stage and Route of Administration, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 22
Pipeline by Anthera Pharmaceuticals‚ Inc., H2 2016 23
Pipeline by Eli Lilly and Company, H2 2016 24
Pipeline by GlaxoSmithKline Plc, H2 2016 25
Pipeline by Merck KGaA, H2 2016 26
Dormant Projects, H2 2016 48
Discontinued Products, H2 2016 49
List of Figures
Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Top 10 Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Actions, H2 2016 18
Number of Products by Routes of Administration, H2 2016 19
Number of Products by Stage and Routes of Administration, H2 2016 19
Number of Products by Molecule Types, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 21
